CONFORMATIONAL DETERMINANTS OF AGONIST VERSUS ANTAGONIST PROPERTIES OF [D-PEN(2),D-PEN(5)]ENKEPHALIN (DPDPE) ANALOGS AT OPIOID RECEPTORS - COMPARISON OF X-RAY CRYSTALLOGRAPHIC STRUCTURE, SOLUTION H-1-NMR DATA,AND MOLECULAR DYNAMIC SIMULATIONS OF [L-ALA(3)]DPDPE AND [D-ALA(3)]DPDPE
N. Collins et al., CONFORMATIONAL DETERMINANTS OF AGONIST VERSUS ANTAGONIST PROPERTIES OF [D-PEN(2),D-PEN(5)]ENKEPHALIN (DPDPE) ANALOGS AT OPIOID RECEPTORS - COMPARISON OF X-RAY CRYSTALLOGRAPHIC STRUCTURE, SOLUTION H-1-NMR DATA,AND MOLECULAR DYNAMIC SIMULATIONS OF [L-ALA(3)]DPDPE AND [D-ALA(3)]DPDPE, Journal of the American Chemical Society, 118(9), 1996, pp. 2143-2152
c-[D-Pen(2),D-Pen(5)]enkephalin (DPDPE, 1) is a cyclic, constrained, h
ighly potent, delta opioid receptor selective peptide agonist. Substit
ution of Gly(3) with L-Ala in DPDPE to give [L-Ala(3)]DPDPE (2) has be
en shown to produce a peptide with much greater delta receptor binding
selectivity than DPDPE itself. However [L-Ala(3)]DPDPE is only a part
ial agonist in in vivo antinociception and actually was found to poten
tly antagonize the antinociceptive effects of DPDPE at delta receptors
in the brain. In comparison, [D-Ala(3)]DPDPE (3) is a weak and poorly
selective delta agonist. In an effort to correlate the biological pro
files of these peptides with secondary structure, [L-Ala(3)]DPDPE and
[D-Ala(3)]DPDPE were studied by X-ray crystallography and H-1 and C-13
NMR in DMSO solution. Crystals of both peptides were obtained using v
apor diffusion techniques. [L-Ala(3)]DPDPE crystallizes in the monocli
nic space group C2 with cell dimensions a = 36.35(1) Angstrom, b = 19.
737(4) Angstrom, c = 28.16(1) Angstrom, beta = 129.07(2)degrees, and V
= 15688(9) Angstrom(3). The asymmetric unit contains four peptide mol
ecules and approximately 20 water molecules, giving a calculated densi
ty of 1.274 g cm(-3). The conformation of all four independent [L-Ala(
3)]DPDPE molecules is essentially the same. [D-Ala(3)]DPDPE crystalliz
es in the monoclinic space group P2(1) with cell dimensions a = 12.271
(2) Angstrom, b = 9.600(a) Angstrom, c = 18.750(4) Angstrom, beta = 10
3.56(2)degrees, and V = 2147.2(7) Angstrom(3). The asymmetric unit con
tains one peptide molecule and 10 molecules of water, giving a calcula
ted density of 1.298 g cm(-3). Comparison of these X-ray structures wi
th the crystal structure previously reported for DPDPE indicates that
there are differences in the disulfide bond region for all three pepti
des. ROEs determined about the disulfide regions of 1-3 in solution ar
e indicative of a high degree of conformational interconversion, while
heteronuclear coupling constants between the D-Pen(2.5) Ha and C gamm
a,gamma' carbons indicate a Strong preference for a gauche (+) chi(1)
angle in 2. The backbone conformations of DPDPE and [D-Ala(3)]DPDPE in
the X-ray structures are virtually identical, while in [L-Ala(3)]DPDP
E, there is a rotation of approximately 160 degrees about both psi(2)
and phi(3) compared to DPDPE which has the effect of rotating this ami
de group approximately 180 degrees relative to DPDPE. The solution NMR
data for the peptide backbone conformations of 2 and 3 are mainly con
sistent with their X-ray structures. However, MD simulation of all thr
ee compounds, starting with the geometries of their X-ray structures,
indicates that by comparison of observed and predicted ROE intensities
an equilibrium between these conformations is likely in solution. The
''DPDPE-like'' conformation for [L-Ala(3)]DPDPE is however significan
tly higher in energy than the X-ray structure reported here and, thus,
is predicted to be less populated in solution and in receptor binding
. It is concluded that the X-ray structure of DPDPE represents an agon
ist conformation for this peptide at the delta opioid receptor and tha
t the corresponding X-ray structure of [L-Ala(3)]DPDPE represents an a
ntagonist conformation due to the differences in conformation between
positions 2 and 3. Considerations on the structural implications of th
is conformational difference on receptor binding are discussed.